$ISRG

Brosius Mark sold $20K of ISRG

Brosius Mark (EVP & Chief Mfg and Supply Cha) sold 48 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $413.19 ($412.16–$414.13) across 2 trades over 2026-06-11 to 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brosius Mark
Published Jun 12, 2026, 10:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

Provides transparency on officer selling activity; does not include any new business, regulatory, or financial guidance information.

02

Market read

Traders may note the disclosure for sentiment/positioning, but it is unlikely to drive a fundamental repricing on its own.

03

What to watch

The transaction size is small and the plan is pre-arranged, so the signal-to-noise for price impact is typically low.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-12 (covers sales on 2026-06-11 to 2026-06-12).

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Insider Form 4 shows ISRG EVP & Chief Mfg and Supply Chain Brosius Mark sold $19,832.93 of shares via a 10b5-1 plan (48 shares).

Expected impact

Low near-term impact; any effect should be dominated by market-wide factors rather than this transaction.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by an officer, with small dollar value relative to typical ISRG trading/market cap and no accompanying operational or guidance change disclosed.

Market effects

Minimal—this is company-specific insider transaction disclosure, not a sector catalyst.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal views on valuation; traders may still watch for clustering of insider sales across multiple filings.

Key entities

  • ISRG

    Intuitive Surgical, Inc. (subject of the Form 4 insider sale).

  • Brosius Mark

    EVP & Chief Mfg and Supply Chain; sold 48 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3